参考文献/References:
1 Aizawa Y,Yoshida K,Kaise N.The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves’ disease prevalence,mechanism and prognosis[J].Clin Endocrinol,1997,46(1):1-5.
2 Yoshida K,Aizawa Y,KaiseN,et al.Role of thyroid-stimulating blocking antibody in patients who developed hypothyroidism within one year after 131I treatment for Graves’ disease[J].Clin Endocrinol,1998,48(1):17-22.
3 Kraiem Z,Newfield RS.Grves’disease in childhood[J].J Pediatric Endocrinol Meyab,2001,14(3):229-243.
4 Pauwels EK,Smit JW,Slats A,et al.Health effects of the rapeutic use of I-131 in hyperthyroidism[J].Q J Nucl Med,2000,44(4):333-339.
5 Raham MA,Birrell G,Stewart H,et al.Successful radioiodine treatment in a 3 years old child with Grave’s disease following antithyroid medication induced neutropenia[J].Arch Dis Child,2003,88(2):158-159.
6 Zdrojewicz Z,Gawry G,Tuckendlen R,et al.Thyrotoxicosis:indications and contraindications for radioiodine treatment[J].Wiad Lek,2000,53(5-6):346-354.
7 Khanna CM,Sankar R,Magdum M,et al.Early development of transient hypothyroidism after I-131 therapy for thyrotoxicosis[J].J Assoc Physician India,1998,46(3):268-272.
8 Kok SW,Smit JW,de Craen AJ,et al.Clinical outcome after standardized verus dosimetric radioiodine treatment of hyperthyroidism:an equivalence study[J].Nucl Med Commun,2000,21(11):1071-1078.
9 Nebesio TD,Siddiqui AR,Pescovitz OH,et al.Time course to hyperthyroidism after fixed-dose radioablation therapy of Graves’ disease in children[J].J Pediatr,2002,141(1):99-103.
10 Allahabadia A,Daykin J,Sheppard MC,et al.Radioiodine treatment of hyperthyroidism prognostic factors for outcome[J].J Clin Endocrinol Metab,2001,86(8):3611-3617.
11 Bakken SC,Zanin DE,Zweers EJ.Treatment of hyperthyroidism caused by Graves’ disease or toxic multinodular goiter by radioiodine:over 80% cure retrospectively after one calculated dose[J].Ned Tijdschr Geneeskd,2002,146(39):1837-1841.
12 Andrade VN,Gross JL,Maia AL,et al.The effect of methimazole pretreatment on the efficacy of radioiodine therapy in Grave’s hyperthyroidism:one-year follow-up of a prospective randomized study[J].J Clin Endocrinol Metab,2001,86(8):3488-3489.
13 Haase A,Bahre M,Lauser I,et al.Radioiodine therapy in Graves’ hyperthyroidism:determination of individual optium target dose[J].Exp Clin Endocrinol Diabetes,2000,108(2):133-137.
14 Kaplan MM,Meier DA,Dworkin HJ.Treatment of hyperthroidism with radioactive iodine[J].Endocrinol Metab clin North Am,1998,27(1):205-223.
15 Gomez JM,Gomez N,Amat M,et al.Hypothyroidism after iodine-131 or surgical therapy for Graves’ disease hyperthyroidism[J].AnnEndocrinol,2000,61(3):184-191.
16 Cooper DS,Ridgway EC.Thoughts on prevention of thyroid disease in United States[J].Thyroid,2002,12(10):925-929.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]贾强,孟召伟,谭建.异位甲状腺发病机理、诊断与治疗的研究进展[J].国际放射医学核医学杂志,2016,40(4):297.[doi:10.3760/cma.j.issn.1673-4114.2016.04.012]
Jia Qiang,Meng Zhaowei,Tan Jian.Progress of pathogenisis, diagnosis and treatment of ectopic thyroid[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):297.[doi:10.3760/cma.j.issn.1673-4114.2016.04.012]
[4]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[5]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[6]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[7]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[8]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[9]孟召伟,谭建.美国甲状腺协会和临床内分泌医师协会2012年甲减诊治指南介绍[J].国际放射医学核医学杂志,2013,37(2):124.[doi:10.3760/cma.j.issn.1673-4114.2013.02.016]
MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hypothyroidism published in 2012 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):124.[doi:10.3760/cma.j.issn.1673-4114.2013.02.016]
[10]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[11]郭永铁.促甲状腺激素与亚临床性甲状腺功能异常[J].国际放射医学核医学杂志,2008,32(6):351.
GUO Yong-tie.Thyroid stimulating hormone and subclinical thyroid dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):351.
[12]王金萍,吴秋莲,徐浩.甲状腺功能与血清饥饿素和瘦素水平的相关陛研究[J].国际放射医学核医学杂志,2008,32(4):221.
WANG Jin-Lian,WU Qiu-lion,XU Hao.Association of thyroid function with human serum ghrelin and leptin levels[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):221.
[13]陈再君,蒋宁一.131I治疗甲亢后致甲减的研究变迁[J].国际放射医学核医学杂志,2004,28(4):153.
CHEN Zai-jun,JIANG Ning-yi.The research vicissitudes of hypothyroidism after 131I therapy for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):153.